451 Correlative and updated clinical endpoint analysis of a multicenter phase II trial of selumetinib (AZD6244) plus erlotinib in chemotherapy-refractory advanced pancreatic adenocarcinoma (PDAC)
Ko, A.H., Tempero, A.H., Bekaii-Saab, T.B., Kuhn, P., Courtin, R., Ziyeh, S., Tahiri, S., Kelley, R.K., Dito, E., Ong, A., Linetskaya, R., Talasaz, A., Venook, A.P., Korn, W.Volume:
50
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(14)70577-5
Date:
November, 2014
File:
PDF, 60 KB
english, 2014
File converter
More search results
More benefits 
